VERICEL CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VERICEL CORPORATION (VCEL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $36.49 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-02-27
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $7.92M.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $9.22M, a 16.41% increase year-over-year.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $9.52M, a 8.66% increase year-over-year.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $9.83M, a 12.63% increase year-over-year.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $36.49M, a 12.90% increase from fiscal 2023.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $32.33M, a 13.07% decline from fiscal 2022.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $37.18M, a 8.34% increase from fiscal 2021.
- VERICEL CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $34.32M, a 147.94% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 243 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 255 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 261 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $7.92M derived: 10-K 12 month − 3 quarters · filed 2025-02-27 | $17.14M derived: sum of 2 quarters · filed 2025-02-27 | $26.66M derived: sum of 3 quarters · filed 2025-02-27 | $36.49M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $9.22M 10-Q · filed 2024-11-07 | $18.74M derived: sum of 2 quarters · filed 2024-11-07 | $28.58M derived: sum of 3 quarters · filed 2024-11-07 | ||||
| 2024-06-30 | $9.52M 10-Q · filed 2024-11-07 | $19.35M derived: sum of 2 quarters · filed 2024-11-07 | |||||
| 2024-03-31 | $9.83M 10-Q · filed 2024-11-07 | ||||||
| 2023-12-31 | $32.33M 10-K · filed 2025-02-27 | ||||||
| 2023-09-30 | $7.92M 10-Q · filed 2024-11-07 | $16.68M derived: sum of 2 quarters · filed 2024-11-07 | $25.42M derived: sum of 3 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $8.76M 10-Q · filed 2024-11-07 | $17.49M derived: sum of 2 quarters · filed 2024-11-07 | |||||
| 2023-03-31 | $8.73M 10-Q · filed 2024-11-07 | ||||||
| 2022-12-31 | $37.18M 10-K · filed 2025-02-27 | ||||||
| 2022-09-30 | $9.10M 10-Q · filed 2023-11-08 | $19.91M derived: sum of 2 quarters · filed 2023-11-08 | $29.44M derived: sum of 3 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $10.81M 10-Q · filed 2023-11-08 | $20.34M derived: sum of 2 quarters · filed 2023-11-08 | |||||
| 2022-03-31 | $9.53M 10-Q · filed 2023-11-08 | ||||||
| 2021-12-31 | $34.32M 10-K · filed 2024-02-29 | ||||||
| 2021-09-30 | $8.60M 10-Q · filed 2022-11-09 | $19.46M derived: sum of 2 quarters · filed 2022-11-09 | $26.48M derived: sum of 3 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $10.87M 10-Q · filed 2022-11-09 | $17.89M derived: sum of 2 quarters · filed 2022-11-09 | |||||
| 2021-03-31 | $7.02M 10-Q · filed 2022-11-09 | ||||||
| 2020-12-31 | $13.84M 10-K · filed 2023-02-23 | ||||||
| 2020-09-30 | $2.67M 10-Q · filed 2021-11-09 | $7.05M derived: sum of 2 quarters · filed 2021-11-09 | $10.82M derived: sum of 3 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $4.38M 10-Q · filed 2021-11-09 | $8.14M derived: sum of 2 quarters · filed 2021-11-09 | |||||
| 2020-03-31 | $3.77M 10-Q · filed 2021-11-09 | ||||||
| 2019-12-31 | $13.18M 10-K · filed 2022-02-24 | ||||||
| 2019-09-30 | $3.29M 10-Q · filed 2020-11-05 | $7.47M derived: sum of 2 quarters · filed 2020-11-05 | $10.10M derived: sum of 3 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $4.18M 10-Q · filed 2020-11-05 | $6.81M derived: sum of 2 quarters · filed 2020-11-05 | |||||
| 2019-03-31 | $2.63M 10-Q · filed 2020-11-05 | ||||||
| 2018-12-31 | $7.22M 10-K · filed 2021-02-24 | ||||||
| 2018-09-30 | $1.93M 10-Q · filed 2019-11-05 | $4.40M derived: sum of 2 quarters · filed 2019-11-05 | $5.75M derived: sum of 3 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $2.46M 10-Q · filed 2019-11-05 | $3.81M derived: sum of 2 quarters · filed 2019-11-05 | |||||
| 2018-03-31 | $1.35M 10-Q · filed 2019-11-05 | ||||||
| 2017-12-31 | $2.68M 10-K · filed 2020-02-25 | ||||||
| 2016-12-31 | $2.50M 10-K · filed 2019-02-26 | ||||||
| 2015-12-31 | $2.75M 10-K · filed 2018-03-05 | ||||||
| 2014-12-31 | $839.00K 10-K · filed 2017-03-13 | ||||||
| 2013-12-31 | $926.00K 10-K · filed 2015-03-25 | ||||||
| 2012-12-31 | $3.61M 10-K · filed 2014-03-13 | ||||||
| 2011-12-31 | $3.74M 10-K · filed 2014-03-13 | ||||||
| 2010-12-31 | $1.04M 10-K · filed 2013-03-18 | $10.13M 10-K · filed 2014-03-13 | |||||
| 2010-06-30 | $710.00K 10-K · filed 2012-03-15 | $9.09M 10-K · filed 2013-03-18 | |||||
| 2009-06-30 | $8.38M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |